LON:HEMO - Hemogenyx Pharmaceuticals Stock Price, Price Target & More

GBX 3.21 -0.02 (-0.62 %)
(As of 04/23/2018 03:30 AM ET)
Previous CloseGBX 3.23
Today's RangeGBX 3.21 - GBX 3.21
52-Week RangeGBX 2 - GBX 6.80
Volume81,755 shs
Average Volume8.01 million shs
Market Capitalization£10.35 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Hemogenyx Pharmaceuticals (LON:HEMO)

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning; and Hu-PHEC, a cell therapy product for bone marrow/hematopoietic stem cells transplantation. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Receive HEMO News and Ratings via Email

Sign-up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolLON:HEMO
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-44.09%
Return on Assets-36.07%

Miscellaneous

EmployeesN/A
Outstanding Shares356,040,000

How to Become a New Pot Stock Millionaire

Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions

What is Hemogenyx Pharmaceuticals' stock symbol?

Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO."

Who are some of Hemogenyx Pharmaceuticals' key competitors?

Who are Hemogenyx Pharmaceuticals' key executives?

Hemogenyx Pharmaceuticals' management team includes the folowing people:
  • Sir Marc Feldmann, Exec. Chairman
  • Dr. Vladislav Sandler Ph.D., Co-Founder & CEO
  • Ms. Alexis M. Sandler J.D., Co-Founder & COO
  • Mr. Timothy Vincent Le Druillenec FCMA, Fin. Director & Company Sec. (Age 57)
  • Mr. Lawrence Pemble, Chief Operating Officer

Has Hemogenyx Pharmaceuticals been receiving favorable news coverage?

Headlines about HEMO stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hemogenyx Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the company an impact score of 45.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Hemogenyx Pharmaceuticals?

Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hemogenyx Pharmaceuticals' stock price today?

One share of HEMO stock can currently be purchased for approximately GBX 3.21.

How big of a company is Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals has a market capitalization of £10.35 million.


MarketBeat Community Rating for Hemogenyx Pharmaceuticals (HEMO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about Hemogenyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe HEMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEMO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hemogenyx Pharmaceuticals (LON:HEMO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/23/2016 forward)

Earnings

Dividends

Hemogenyx Pharmaceuticals (LON:HEMO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Hemogenyx Pharmaceuticals (LON HEMO) Insider Trading and Institutional Ownership History

Insider Trading History for Hemogenyx Pharmaceuticals (LON:HEMO)

Hemogenyx Pharmaceuticals (LON HEMO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Adrian BeestonInsiderBuy200,000GBX 2£4,000
10/6/2017Adrian BeestonInsiderBuy10,000GBX 3£300
(Data available from 1/1/2013 forward)

Headlines

Hemogenyx Pharmaceuticals (LON HEMO) News Headlines

Source:

SEC Filings

Hemogenyx Pharmaceuticals (LON:HEMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Hemogenyx Pharmaceuticals (LON HEMO) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.